← All indications
Liver Neoplasms
Tumors or cancer of the LIVER.
Subtype terms (3)
More specific conditions that are subtypes of Liver Neoplasms in the MeSH hierarchy.
- Adenoma, Liver Cell
3 drugs (2 approved, 1 experimental)
- Carcinoma, Hepatocellular
751 drugs (224 approved, 527 experimental)
- Liver Neoplasms, Experimental
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (39)
- Galactose
- entecavir
- pregabalin
- human papillomavirus 9-valent vaccine, recombinant
- oxaliplatin
- enoxaparin
- dalteparin
- fluorouracil
- apixaban
- Gadoxetic acid
- cetuximab
- vasopressin
- gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
- Raltitrexed
- tinzaparin
- atezolizumab
- sevoflurane
- icosapent ethyl
- ropivacaine
- fentanyl
- chlorhexidine
- warfarin
- hepatitis b vaccine (recombinant)
- propofol
- albumin (Human)
- nivolumab
- lamivudine
- sodium chloride
- nicotine
- dexmedetomidine
- +9 more
Phase 3 trials (56)
- regorafenib
- cisplatin
- pi-88
- arginine
- irinotecan
- ipilimumab
- Paltusotine
- gimeracil
- vincristine
- prunus domestica
- megestrol
- perfluorobutane
- brivanib alaninate
- gemcitabine
- etoposide
- toripalimab
- lobaplatin
- amifostine
- hepcortespenlisimut-l
- iodine
- oteracil
- tivantinib
- sulfur hexafluoride lipid-type a microspheres
- escitalopram
- ytttrium-90 microspheres
- sunitinib
- floxuridine
- pravastatin
- sodium thiosulfate
- lidocaine
- +26 more
Phase 2 trials (209)
- vitamin c
- trastuzumab emtansine
- levoleucovorin
- sargramostim
- vinblastine
- trametinib
- fludeoxyglucose f-18
- nci-4650
- ab154
- dostarlimab
- myoinositol
- glucose monohydrate
- t3011
- taselisib
- adebrelimab
- tiragolumab
- q702
- human choriogonadotropin alfa
- typhoid vaccine
- fpi-1966
- bms-986218
- binimetinib
- erlotinib
- pemetrexed
- ect204 t cells
- alvocidib
- xiaochaihu-tang
- chidamide
- autologous natural killer cells
- octreotide
- +179 more
Phase 1 trials (106)
- p-il-2
- ropidoxuridine
- recombinant adenoviral human p53 gene
- erx-315
- cd133 car-t cells
- BST02
- hgm-csf herpes simplex virus injection
- veliparib
- etn101
- irx-2
- prostate specific membrane antigen
- sm04755
- abituzumab
- gadoxetate disodium
- taest16001
- gap t cells
- vitamin d3
- mtl-cebpa
- np-g2-044
- mts105
- dnx-2440
- tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3
- panobinostat
- ye-neo-001
- tbi-1301
- [18f]f-psma-n5
- abt-751
- recombinant fowlpox-cea(6d)/tricom vaccine
- ast-201
- rv-cea(6d)/tricom
- +76 more
Other trials (45)
- technetium tc-99m sulfur colloid kit
- fd-001
- nkt cells
- amino acids
- Lentinula edodes
- valine
- whey protein
- levobupivacaine
- lactobacillus rhamnosus
- ketorolac
- insulin human
- epinephrine
- hydromorphone
- l-isoleucine
- ciprofol
- [68ga]ga-dota-h2d3
- dexamethasone
- beta-elemene
- qy-1-t
- [68ga]ga-nota-g5
- [68ga]ga-nota-t4
- remifentanil
- dextrin
- epcam car-t cells
- acetaminophen
- [18f]f-resca-t4
- [68ga]ga-nota-wwh347
- morphine
- varenicline
- personalized neoantigen vaccine
- +15 more
Organizations
Organization Involved with Phase 4 Indications (28)
- McNeil
- Merck
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Hebei University
- Baylor University
- Changhua Christian Hospital
- Harvard University
- Temple University
- Nanjing Medical University
- Tanta University
- University of Louisville
- Fudan University
- Peking University
- Dalian Medical University
- University of Colorado, Denver
- Uppsala University
- Zhejiang University
- University of Vienna
- Jiao Tong University
- University of Oxford
- Sun Yat-Sen University
- Rocky Mountain Poison and Drug Center
- University of Colorado
- Government of Canada
- Qidong Liver Cancer Institute
- Chinese Academy of Medical Sciences
- Beijing Cancer Hosptial
Organization Involved with Phase 3 Indications (68)
- Abbott
- Bristol-Myers Squibb
- Roche
- Kowa
- Bracco
- Pfizer
- Sanofi
- Novartis
- Chugai
- Cure&Sure Biotech Co., LTD
- Eximias Pharmaceutical
- Immunitor LLC
- Light Sciences Oncology
- Medigen Biotechnology Corporation
- Progen Pharmaceuticals
- Sirtex Medical
- Amarin
- University of Pittsburgh
- Arbeitsgruppe Lebermetastasen und Tumoren
- Cairo University
- Cancer Research Campaign
- Centre Georges Francois Leclerc
- Children's Cancer and Leukaemia Group
- University of London
- Federation Francophone de Cancerologie Digestive
- Guangxi Medical University
- Guangzhou Medical University
- Kyoto University
- Radiation Therapy Oncology Group
- Rocky Mountain Cancer Centers
- +38 more
Organization Involved with Phase 2 Indications (167)
- Daiichi Sankyo
- Eisai
- Amgen
- Onyx
- OSI Pharmaceuticals
- Biocompatibles International plc
- AstraZeneca
- Merck Serono
- Eli Lilly
- Genentech
- MediGene
- Guerbet
- Siemens
- Ipsen
- AIO-Studien-gGmbH
- Arbutus Biopharma Corporation
- Bayer
- Crolll Gmbh
- FeRx
- Hengrui Therapeutics, Inc.
- Medivir
- Matrix Pharmaceutical
- Nanobiotix
- Ningbo Cancer Hospital
- PhytoCeutica
- Shanghai GeneChem Co., Ltd.
- Teclison Ltd.
- Threshold Pharmaceuticals
- Zai Lab Pty. Ltd.
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
- +137 more
Organization Involved with Phase 1 Indications (55)
- Adaptimmune
- Green Cross Corporation
- Merck KGaA
- BTG
- Curis
- Anza Therapeutics, Inc.
- Celldex Therapeutics
- Celsion
- Celyad
- GlaxoSmithKline
- Gradalis, Inc.
- Leadiant Biosciences, Inc.
- Mateon Therapeutics
- Mereo BioPharma
- Mina Alpha Limited
- Onconova Therapeutics, Inc.
- Biosplice Therapeutics
- Simcere Pharmaceutical Co., Ltd
- Sirnaomics
- Translational Drug Development
- University of Roma La Sapienza
- University of Pennsylvania
- Cancer and Leukemia Group B (CALGB)
- Medical College of Wisconsin
- Monash University
- Rhode Island Hospital
- Stanford University
- University of Nebraska
- University of Adelaide
- Virginia Commonwealth University
- +25 more
Organization Involved with Other Experimental Indications (17)
- Beijing Yijiayi Medicine Techonoloy Co., Ltd.
- Sinobioway Cell Therapy Co., Ltd.
- University of Manitoba
- Harbin Medical University
- Mahidol University
- McGill University
- Melbourne Health
- Siriraj Hospital
- Tufts University
- University of Hamburg
- University of Kansas
- Vita-Salute University of Milano. Italy
- University of Alabama, Birmingham
- Dalian Holley Kingkong Pharmaceutical Co., Ltd
- Surefire Medical, Inc.
- American College of Radiology
- Northeast Ohio Medical University